FIELD: biotechnologies.
SUBSTANCE: present invention refers to biotechnology. Presented is a method for producing cytotoxic T lymphocytes expressing a chimeric receptor. According to the presented method, T-lymphocyte transduction is ensured by recombinant lentiviral particles pseudotyped with surface glycoproteins of the vaccine measles virus strain, and lentiviral particles are developed using a CD46-deficient packer line produced using an expression construct for expressing the CRISPR/Cas9 enzyme and RNA guide (sgRNA), complementary to a portion of one of the exons of the CD46 gene.
EFFECT: method advantage is caused by efficiency of lentiviral particles production due to minimization of negative effects of formation of syncytium and virus reabsorption by packing line cells.
1 cl, 7 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| AUXILIARY PLASMID LENTIVIRAL EXPRESSION VECTOR FOR OBTAINING HIGH TITERS OF Vpx-CONTAINING LENTIVIRAL PARTICLES, WHICH PROVIDES EFFECTIVE INFECTION OF HUMAN MONOCYTES AND DENDRITIC CELLS | 2017 |
|
RU2697781C2 |
| RECOMBINANT STRAIN OF HERPESVIRUS SAIMIRI FOR OBTAINING POPULATIONS OF IMMORTALISED AUTOLOGOUS T LYMPHOCYTES EXPRESSING PAIRED CHIMERIC RECEPTORS AGAINST CD44 AND CD133 TUMOUR ANTIGENS | 2020 |
|
RU2771081C2 |
| METHOD FOR PRODUCING RECOMBINANT HERPESVIRUSES FOR SIMULTANEOUS TRANSDUCTION AND IMMORTALIZATION OF PRIMARY T-LYMPHOCYTES AND NK CELLS | 2019 |
|
RU2751482C2 |
| LENTIVIRAL VECTORS PSEUDOTYPED BY MUTANT BaEV GLYCOPROTEINS | 2012 |
|
RU2618864C2 |
| PSCA-CAR-YT CELL LINE HAVING SURFACE EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS AND EXHIBITING CYTOTOXIC ACTIVITY ON PSCA-POSITIVE HUMAN CANCER CELLS | 2018 |
|
RU2712901C1 |
| RECOMBINANT CYTO-CAR-YT-LACT CELL LINE EXHIBITING HIGH CYTOTOXIC ACTIVITY WITH RESPECT TO PSCA-POSITIVE HUMAN CANCER CELLS | 2019 |
|
RU2724431C1 |
| SCALE PRODUCTION METHOD OF PRODUCING RECOMBINANT LENTIVIRAL VECTORS IN CELL CULTURE SYSTEM IN SERUM-FREE SUSPENSION | 2014 |
|
RU2709678C2 |
| RECOMBINANT CELL LINE TMDK562-15 SHOWING THE ABILITY TO ACTIVATE AND PROLIFERATE HUMAN NK CELLS | 2022 |
|
RU2803178C1 |
| METHOD OF OBTAINING SYSTEM OF DIRECTED DELIVERY OF PROTEIN MOLECULES (ONCOLYTIC PROTEINS) INTO TUMOUR CELLS BASED ON ACTIVATED LYMPHOCYTES | 2013 |
|
RU2552609C1 |
| SEMISTABLE PRODUCTION OF LENTIVIRUS VECTORS | 2011 |
|
RU2577982C2 |
